公开(公告)号：US10941216B2

公开(公告)日：2021-03-09

申请号：US15593259

申请日：2017-05-11

Applicant: PFIZER INC. ,  RINAT NEUROSCIENCE CORP.

Inventor： Pavel Strop ,  Magdalena Grazyna Dorywalska ,  Arvind Rajpal ,  David Shelton ,  Shu-Hui Liu ,  Jaume Pons ,  Russell Dushin

IPC: A61K47/68 ,  C07K16/00 ,  C07K17/02 ,  A61P43/00 ,  C07K16/30

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

公开(公告)号：US10294304B2

公开(公告)日：2019-05-21

申请号：US15085317

申请日：2016-03-30

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/63 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  A61K31/7076 ,  A61K35/17 ,  A61K38/00

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US09969809B2

公开(公告)日：2018-05-15

申请号：US15085644

申请日：2016-03-30

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K47/48 ,  A61K31/69 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US11814435B2

公开(公告)日：2023-11-14

申请号：US17005073

申请日：2020-08-27

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  C07K16/2803 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US11602525B2

公开(公告)日：2023-03-14

申请号：US15306481

申请日：2015-04-21

Applicant: RINAT NEUROSCIENCE CORP. ,  PFIZER INC.

Inventor： Pavel Strop ,  Katherine Anne Delaria ,  Magdalena Dorywalska ,  Davide Luciano Foletti ,  Russell George Dushin ,  David Louis Shelton ,  Arvind Rajpal

IPC: A61K31/427 ,  A61K47/68 ,  A61K47/65 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.

公开(公告)号：US11155630B2

公开(公告)日：2021-10-26

申请号：US17129833

申请日：2020-12-21

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

公开(公告)号：US10040860B2

公开(公告)日：2018-08-07

申请号：US15878344

申请日：2018-01-23

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K47/68 ,  A61K31/69 ,  A61K31/704 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US20140342450A1

公开(公告)日：2014-11-20

申请号：US14244167

申请日：2014-04-03

Applicant: Amgen Fremont Inc. ,  Pfizer Inc.

Inventor： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina L. Liang

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

Abstract translation: 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。